Imagine your nerves are like frayed electrical wires that cause 'static' in the form of pain or silence in the form of deafness. Instead of just masking the symptoms with painkillers, these proteins act like a repair kit to fix the wires and the insulation around them. This helps the body heal the actual damage rather than just numbing the feeling.
Current treatments for chronic pain rely on CNS drugs that cause cognitive impairment and addiction, while hearing loss has no reparative medical options beyond amplification devices.
Two therapeutic proteins, HB-086 and HB-097, designed to regenerate sensory nerve fibers and normalize neuronal-glial crosstalk.
If you are a biotech drug developer dealing with the high failure rate of CNS-targeting painkillers — this project developed HB-086 and HB-097 that target sensory nerve cells directly to abolish pain without the dizziness or addiction associated with opioids.
If you are a medical therapy provider dealing with the limitation that hearing aids only amplify sound but cannot fix nerves — this project developed HB-097 that preserves the sense of hearing by protecting sensory nerve fibers.
If you are a cancer care clinic dealing with patients who stop chemotherapy due to chronic nerve pain — this project developed a protein therapy that prevents and treats chemotherapy-induced pain to improve patient survival rates.
Based on available project data, specific pricing and cost structures are not provided.
Based on available project data, the project focuses on preclinical validation and therapeutic protein development; industrial scaling details are not mentioned.
Hoba Therapeutics holds the rights to and is developing the two molecules, HB-086 and HB-097.
The documented prolonged effects of the proteins warrant biweekly or monthly dosing.
It serves as a replacement or alternative to antiepileptics, antidepressants, and opioids by targeting the peripheral sensory system instead of the central nervous system.
The project is led by a single SME, Hoba Therapeutics ApS from Denmark. With a 100% industry ratio and no university or research institute partners, the project is streamlined for commercial development and direct control of the intellectual property.
Contact Hoba Therapeutics ApS in Denmark
Contact us to explore licensing opportunities for HB-086 and HB-097.
